Top Biotech Stocks To Invest In 2019

Introduction

Roche ADRs (OTCQX:RHHBY) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December’s US tax legislation. Coming into the important ASCO (oncology) meeting this weekend, this article provides an update on this mega-cap in view of the conflict between several pieces of positive news flow and the steady move down in the stock.

RHHBY is both the world’s largest biotech company and the world’s largest diagnostics company. The current yield is 4.0%; I expect about a 5% increase in the dividend next year, so I am looking at this security as carrying a forward yield of 4.2%. RHHBY could cut a good deal from R&D and would still be spending a higher proportion of pharma revenues on R&D than Merck (MRK) or Pfizer (PFE). So why does the stock chart look like this, relative to the S&P 500 (SPY) – of which it is not a member, being a Swiss company – or a pharma stock index (DRG)?

Top Biotech Stocks To Invest In 2019: JetPay Corporation(JTPY)

Advisors’ Opinion:

  • [By Joseph Griffin]

    JetPay (NASDAQ:JTPY) posted its quarterly earnings results on Thursday. The credit services provider reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03), Fidelity Earnings reports. The company had revenue of $15.87 million during the quarter, compared to analyst estimates of $19.33 million. JetPay had a negative net margin of 4.54% and a negative return on equity of 305.34%.

Top Biotech Stocks To Invest In 2019: Celyad SA(CYAD)

Advisors’ Opinion:

  • [By Joseph Griffin]

    CELYAD SA/ADR (NASDAQ:CYAD) has received a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $47.50.

  • [By Lisa Levin] Gainers
    Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 29.4 percent to $5.50 in pre-market trading after the company disclosed that its first pivotal Phase 3 trial of IV tramadol achieved the primary and key secondary endpoints.
    MB Financial, Inc. (NASDAQ: MBFI) rose 16.8 percent to $51.00 in pre-market trading. Fifth Third Bancorp (NASDAQ: FITB) agreed to acquire MB Financial for $54.70 per share in cash and stock.
    LiveXLive Media, Inc. (NASDAQ: LIVX) rose 9.3 percent to $5.40 in pre-market trading after falling 28.92 percent on Friday.
    Celyad SA (NASDAQ: CYAD) shares rose 9 percent to $29.30 in pre-market trading after climbing 3.26 percent on Friday.
    Ethan Allen Interiors Inc. (NYSE: ETH) rose 6.7 percent to $26.40 in pre-market trading after gaining 1.64 percent on Friday.
    Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) rose 5.4 percent to $3.90 in pre-market trading after gaining 3.06 percent on Friday.
    Acacia Communications, Inc. (NASDAQ: ACIA) rose 5.2 percent to $34.70 in pre-market trading after gaining 1.38 percent on Friday.
    Westinghouse Air Brake Technologies Corporation (NYSE: WAB) rose 5.1 percent to $100 in pre-market trading. General Electric Company (NYSE: GE) agreed to merge its transportation unit with Wabtec.
    Sunrun Inc. (NASDAQ: RUN) shares rose 4.7 percent to $11.50 in pre-market trading.
    Nasdaq, Inc. (NASDAQ: NDAQ) shares rose 4.3 percent to $93.98 in the pre-market trading session.
    LaSalle Hotel Properties (NYSE: LHO) shares rose 4.2 percent to $33.25 in pre-market trading. Blackstone Group LP (NYSE: BX) will buy LaSalle Hotel Properties in a $4.8 billion deal, Bloomberg reported.
    Monro, Inc. (NASDAQ: MNRO) shares rose 4 percent to $58.35 in pre-market trading as the company posted upbeat quarterly earnings and disclosed that it has acquired Free Service Tire.
    HUYA Inc. (NYSE: HUYA) rose 3.7 percent to $19.75 in pre-market trading after falling 4.80 percent on Friday.

    Find out what's going

  • [By Max Byerly]

    Shares of CELYAD SA/ADR (NASDAQ:CYAD) have been assigned a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $53.00.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Verastem, Inc. (NASDAQ: VSTM) fell 9.7 percent to $4.73 in pre-market trading after announcing a $35 million common stock offering.
    Evolus, Inc. (NASDAQ: EOLS) shares fell 8 percent to $13.48 in pre-market trading ahead of regulatory update at 8:30 a.m. ET.
    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) fell 6.5 percent to $2.01 in pre-market trading after climbing 10.50 percent on Tuesday.
    Purple Innovation, Inc. (NASDAQ: PRPL) shares fell 5.8 percent to $9.36 in pre-market trading after reporting Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) fell 5.7 percent to $5.15 in pre-market trading after declining 5.04 percent on Tuesday.
    RYB Education, Inc. (NYSE: RYB) shares fell 5 percent to $16.39 in pre-market trading following Q1 results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares fell 4.4 percent to $4.30 in pre-market trading after rising 40.62 percent on Tuesday.
    Arbor Realty Trust, Inc. (NYSE: ABR) fell 4.4 percent to $8.92 in pre-market trading after announcing a 5.5 million share common stock offering.
    Daxor Corporation (NYSE: DXR) fell 4.1 percent to $7.32 in pre-market trading.
    Ormat Technologies, Inc. (NYSE: ORA) shares fell 3.8 percent to $51.03 in pre-market trading after the company announced plans to restate its Q2, Q3, Q4 and FY 2017 financial statements.
    Canadian Solar Inc. (NASDAQ: CSIQ) fell 3.5 percent to $16.20 in pre-market trading after reporting Q1 results.
    CELYAD SA/ADR (NASDAQ: CYAD) shares fell 3.3 percent to $29.70 in pre-market trading after the company reported launch of 1.8 million share offering

  • [By Lisa Levin]

    Breaking news

    Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis, Inc. (NASDAQ: ABAX) for $83 per share in cash.
    Boot Barn Holdings Inc (NYSE: BOOT) reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    CELYAD SA/ADR (NASDAQ: CYAD) reported launch of 1.8 million share offering.
    Verastem Inc (NASDAQ: VSTM) shares dropped 12 percent in pre-market trading after announcing a $35 million common stock offering.

Top Biotech Stocks To Invest In 2019: Home BancShares, Inc.(HOMB)

Advisors’ Opinion:

  • [By Tim Melvin]

    This was especially the case with Home BancShares Inc. (NASDAQ: HOMB), a regional bank based out of Conway, Arkansas.

    On a Friday afternoon back in summer 2016, I was wrapping up my work and heading out for my “ready for the weekend pizza and vino” run when I got an email from Home BancShares chairman John Allison.

  • [By Joseph Griffin]

    Home BancShares (NASDAQ:HOMB) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Home Bancshares (HOMB)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Home Bancshares (HOMB)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *